Zentalis Pharmaceuticals, Inc.
Income Statement
| Line Item | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $26.9M | $0 | $0 | $40.6M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $29.5M | $23.0M | $27.6M | $27.2M | $33.0M | $36.8M | $48.4M | $49.6M |
| SG&A Expense | $7.9M | $10.8M | $8.4M | $10.6M | $40.0M | $14.6M | $16.8M | $15.7M |
| Operating Income | $-37.4M | $-33.7M | $-36.1M | $-45.6M | $-49.8M | $-51.4M | $-65.1M | $-24.8M |
| Operating Margin | — | — | — | — | -185.6% | — | — | -61.1% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-34.8M | $-26.7M | $-26.9M | $-48.3M | $-47.7M | $-40.2M | $-88.0M | $10.2M |
| Income Tax Expense | $442.0K | $0 | $0 | $0 | $-205.0K | $-27.0K | $266.0K | $143.0K |
| Net Income | $-35.2M | $-26.7M | $-26.9M | $-48.3M | $-47.5M | $-40.2M | $-88.3M | $10.1M |
| Net Margin | — | — | — | — | -176.7% | — | — | 24.8% |
| EPS (Basic) | $-0.50 | $-0.37 | $-0.37 | $-0.67 | $-0.67 | $-0.56 | $-1.24 | $0.14 |
| EPS (Diluted) | $-0.50 | $-0.37 | $-0.37 | $-0.67 | $-0.67 | $-0.56 | $-1.24 | $0.14 |
| Shares Outstanding (Basic) | 71.9M | 72.1M | 72.0M | 71.7M | 71.1M | 71.1M | 71.0M | 70.9M |
| Shares Outstanding (Diluted) | 71.9M | 72.1M | 72.0M | 71.7M | 71.1M | 71.1M | 71.0M | 71.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |